ADQ to acquire leading Turkish pharmaceuticals company Birgi Mefar Group

ADQ to acquire leading Turkish pharmaceuticals company Birgi Mefar Group

- ADQ to acquire leading Turkish Pharmaceutical Contract Development and Manufacturing Organization (CDMO) of sterile solutions and injectables

- Investment expands ADQ’s life sciences capabilities in sterile injectables and wider pharmaceutical services segments, while complementing its broader commitment to Turkey

Abu Dhabi, UAE: ADQ, an Abu Dhabi-based investment and holding company, today announced it has entered into a definitive agreement to acquire Birgi Mefar Group (BMG), one of Turkey’s leading producers of sterile injectable products.

As a full-service pharmaceutical CDMO, BMG is a production service provider for sterile injectable products, namely vials and pre-filled syringes used for vaccines. BMG also produces primary packaging ampoules and vials for other sterile injectables and specializes in the growing demand for drug lyophilization. The company exports to more than 30 countries, including markets across Europe and Asia with more than 50 years of expertise and excellence.

Fahad Al Qassim, Executive Director, Healthcare & Life Sciences Portfolio at ADQ, said: “BMG's diversified offering and manufacturing capabilities make the company a strategic addition to our growing portfolio as we continue to shape the UAE’s healthcare & life sciences platform. Turkey is an important market for our investments, and BMG brings with it a strong presence throughout the pharmaceutical supply chain,